Testing bevacizumab right after eye surgery in people with diabetic eye disease
Tests bevacizumab given right after vitrectomy in adults with high-risk proliferative diabetic retinopathy.
Plain-language title generated from the registry record
Registry title: Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy
Key facts
- Where
- Querétaro City, MexicoSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes and active proliferative diabetic retinopathy in one eye who need vitrectomy surgery.
- Age
- Over 18 years
- Sex
- All sexes can join
- Disease stage
- Active proliferative diabetic retinopathy in the study eye. Vision from 20/40 down to Hand Motions. Surgery is needed mainly because of vitreous hemorrhage, tractional retinal detachment, or fibrous proliferation, each meeting the size or time limits in the record.
- Earlier treatment
- No earlier vitrectomy in the study eye.
Main reasons for not taking part
- Another serious eye disease unrelated to diabetes that causes two or more lines of lost vision
- Significant corneal opacity causing two or more lines of lost vision
- Previous vitrectomy in the study eye
- Uncontrolled neovascular glaucoma (eye pressure above 30 mmHg despite treatment)
- Uncontrolled high blood pressure (systolic above 200 mmHg or diastolic above 120 mmHg)
Read by machine on 12 November 2026.
Where in Mexico
- Sky VisionQuerétaro City, MexicoContact: Isaac Aleman, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Christian Ophthalmic Surgery Expedition Network
- Trial code
- NCT06899529
- Record updated
- 28 March 2025
- Original description
Patients undergoing surgery for complications related to diabetes will be recruited.Read full original descriptionShow less
Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy
Patients undergoing surgery for complications related to diabetes will be recruited.
Inclusion: Subject age is > 18; Subject consents to study participation and is capable of 6 months of follow-up; The subject has type I or II Diabetes Mellitus with active PDR in the study eye; Best-corrected spectacle visual acuity (BCSVA) on the Snellen eye chart ranges from 20/40 to Hand Motions in the study eye; The subject is determined to need a PPV because of reduced BCSVA principally from a non-clearing vitreous hemorrhage, TRD, fibrous proliferation, or a combination of the three. When non-clearing vitreous hemorrhage is the principal reason for PPV, the hemorrhage must have been present by subjective history for at least 3 months. When TRD is the principal reason for PPV, the TRD must be threatening (within one disc diameter) or involving the fovea. When fibrovascular proliferation is the principal reason for PPV, it must be extensive (>3 clock hours) and threatening (within one disc diameter) or involving the fovea; Only one eye per patient is eligible for the study.
Exclusion: Subject has had a previous vitrectomy (anterior or PPV) in the study eye; Subject has uncontrolled neovascular glaucoma (intraocular pressure > 30 mmHg despite medical/surgical treatment) in the study eye; Subject is known to have a significant retinal/optic nerve disease otherwise unrelated to Diabetes Mellitus, which in the opinion of the examiner is responsible for two or more lines of reduced BCSVA (macular degeneration, optic neuritis, glaucoma, amblyopia, etc.) in the study eye; Subject has uncontrolled hypertension (systolic > 200 mmHg or diastolic > 120 mmHg) despite adherence to a multiple anti-hypertensive medication regimen; -; Subject has a significant corneal opacity, which in the opinion of the examiner, is responsible for two or more lines of reduced BCSVA (corneal scar, ectasia, etc.) in the study eye.